SEARCH:   Advanced

Blood, 16 July 2009, Vol. 114, No. 3, pp. 596-599. Prepublished online as a Blood First Edition Paper on May 26, 2009; DOI 10.1182/blood-2009-02-203935. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2009-02-203935v1 114/3/596    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Hinrichs, C. S. Articles by Restifo, N. P. PubMed PubMed Citation Articles by Hinrichs, C. S. Articles by Restifo, N. P. Related Collections Immunobiology Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Brief report Type 17 CD8+ T cells display enhanced antitumor immunity Christian S. Hinrichs1,*, Andrew Kaiser1,*, Chrystal M. Paulos1,*, Lydie Cassard1, Luis Sanchez-Perez1, Bianca Heemskerk2, Claudia Wrzesinski1, Zachary A. Borman1, Pawel Muranski1, and Nicholas P. Restifo1 1 National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD; and 2 Department of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands Interleukin-17 (IL-17)–secreting CD8+ T cells have been described, but they have not been thoroughly studied and they do not have a known role in cancer immunotherapy. We skewed CD8+ T cells to secrete IL-17 through priming in Th17-polarizing conditions. IL-17–producing CD8+ T cells demonstrated reduced expression of Eomes and diminished cytolytic differentiation in vitro. However, after adoptive transfer, these cells converted to interferon-–producing effector cells and mediated regression of large, established tumors. This improved antitumor immunity was associated with increased expression of IL-7R-alpha, decreased expression of killer cell lectin-like receptor G1, and enhanced persistence of the transferred cells. This report is the first description of a cancer therapy with IL-17–secreting CD8+ T cells. These findings have implications for the improvement of CD8+ T cell–based adoptive immunotherapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H.-R. Yen, T. J. Harris, S. Wada, J. F. Grosso, D. Getnet, M. V. Goldberg, K.-L. Liang, T. C. Bruno, K. J. Pyle, S.-L. Chan, et al. Tc17 CD8 T Cells: Functional Plasticity and Subset Diversity J. Immunol., December 1, 2009; 183(11): 7161 - 7168. [Abstract] [Full Text] [PDF] M. L. Disis Enhancing Cancer Vaccine Efficacy via Modulation of the Tumor Microenvironment Clin. Cancer Res., November 1, 2009; 15(21): 6476 - 6478. [Abstract] [Full Text] [PDF] C. S. Hinrichs, Z. A. Borman, L. Cassard, L. Gattinoni, R. Spolski, Z. Yu, L. Sanchez-Perez, P. Muranski, S. J. Kern, C. Logun, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity PNAS, October 13, 2009; 106(41): 17469 - 17474. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020